announced that it’ll present results from a Phase 2a, proof-of-concept research of RDEA594, its lead product applicant for the treatment of gout and hyperuricemia, at the 2009 2009 American University of Rheumatology / Association of Rheumatology Health Professionals Annual Scientific Meeting in Philadelphia, Pennsylvania.0 mg/dL in patients with mild to moderate renal insufficiency, that was the majority of patients randomized to RDEA594.. Ardea’s to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting Ardea Biosciences, Inc.A unique facet of Monomer-Polymer’s chemistries is the internal experience with organosilanes which should open up exclusive uses of RAFT to create polymers with organosilicon functionalities in the architecture. This new technology is creating global influence and has been certified by an array of Australian and multinational businesses, CSIRO’s Business Development Manager for RAFT Kate Dawson stated.

Amgen to provide oncology portfolio results in ESMO Congress Amgen today announced that results from several important studies from the Company’s oncology portfolio will be presented at the 35th European Culture for Medical Oncology Congress, Oct.




COMPANY PROFILE | CUSTOMER SERVICE | PRODUCTS
LEADING PRODUCTS | CATALOGUE | TO CONTACT US

info@uniformetecnic.com